JPS5927333B2 - Process for producing clemastine fumarate useful as a medicine - Google Patents
Process for producing clemastine fumarate useful as a medicineInfo
- Publication number
- JPS5927333B2 JPS5927333B2 JP15796176A JP15796176A JPS5927333B2 JP S5927333 B2 JPS5927333 B2 JP S5927333B2 JP 15796176 A JP15796176 A JP 15796176A JP 15796176 A JP15796176 A JP 15796176A JP S5927333 B2 JPS5927333 B2 JP S5927333B2
- Authority
- JP
- Japan
- Prior art keywords
- acetone
- clemastine
- tartrate
- isomer
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pyrrole Compounds (AREA)
Description
【発明の詳細な説明】
本発明は、2−(2’一〔(パラクロロ−α−メチルー
α−フェニルベンジル)オキシ〕エチル)−1−メチル
ーピロリジンフマール酸塩、即ち「フマール酸クレマス
チン」の製法に係り、殊にその立体異性体混合物より医
薬として有用な異性体の光学分割法に係る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to 2-(2'-[(parachloro-α-methyl-α-phenylbenzyl)oxy]ethyl)-1-methyl-pyrrolidine fumarate, that is, “clemastine fumarate”. The present invention relates to a manufacturing method, and particularly to a method for optical resolution of isomers useful as pharmaceuticals from stereoisomer mixtures.
クレマスチンには2個の不斉炭素原子が存在し、従つて
4種の光学異性体が存在する。Clemastine has two asymmetric carbon atoms and therefore has four optical isomers.
これ等4種の異性体及び有機酸塩の基準となる比旋光度
はそれぞれであるが、抗ヒスタミン作用を示し医薬とし
て殊に重要なのは異性体■である。These four isomers and organic acid salts have different standard specific rotations, but isomer ① exhibits antihistamine action and is particularly important as a medicine.
最近提案されたクレマスチンの光学分割法としては、特
開昭51−105054号公報に記載の方法がある。As a recently proposed optical resolution method for clemastine, there is a method described in JP-A-51-105054.
この公知方法に於ては、光学分割に用いられる一般的光
学活性有機酸、例えば酒石酸、リンゴ酸等を用いる場合
には得られるクレマスチン酸塩が非結晶性であるとして
、分割剤としてジベンゾイルー中又はH−酒石酸を用い
ている。In this known method, when a general optically active organic acid used for optical resolution, such as tartaric acid or malic acid, is used, the cremastate obtained is non-crystalline, and dibenzoyl as a resolving agent is used. Or H-tartaric acid is used.
この公知方法に鑑みて、各種有機酸について分割剤とし
ての使用を検討した処、…又はH−酒石酸はアセトンを
溶媒として用いる場合に有効であるが、精製に際して純
アセトンを再結晶溶媒として用いる場合にはフマール酸
クレマスチンの所望異性体■を得るためにはその再現性
、収率等に問題の生ずることが見出された。In view of this known method, we investigated the use of various organic acids as resolving agents...Although H-tartaric acid is effective when acetone is used as a solvent, when pure acetone is used as a recrystallization solvent during purification. In order to obtain the desired isomer (2) of clemastine fumarate, it was found that problems occurred in reproducibility, yield, etc.
従つて、本発明の目的は、(1)又は(ニ)一酒石酸を
分割剤とし且つアセトンを溶媒としてクレマスチンの異
性体混合物から上記異性体即ち医薬として有用なフマー
ル酸クレマスチンを製造する方法において、再現性が良
好であり且つ収率の高い製法を提供することにある。Therefore, the object of the present invention is to provide (1) or (d) a method for producing the above isomer, ie, clemastine fumarate useful as a pharmaceutical, from a mixture of isomers of clemastine using monotartaric acid as a resolving agent and acetone as a solvent, The object of the present invention is to provide a manufacturing method with good reproducibility and high yield.
本発明によれば、この目的は上記方法において精製用再
結晶溶媒として含水アセトン又は含水エタノールを用い
ることを特徴とする方法により達成される。According to the invention, this object is achieved by a method characterized in that, in the method described above, aqueous acetone or aqueous ethanol is used as the recrystallization solvent for purification.
本発明において含水アセトン又は含水エタノールとは7
0乃至95%アセトン又はエタノール水溶夜を意味する
。In the present invention, aqueous acetone or aqueous ethanol is 7
Means 0 to 95% acetone or ethanol aqueous solution.
本発明方法は以下のように種々の態様で実施することが
できる。The method of the present invention can be carried out in various ways as described below.
先ず、第1方法は、クレマスチンの異性体混合物と(4
)一酒石酸とをアセトンの存在下に反応させ、濾過し、
得られる酒石酸塩よりアセトンを留去し、次いで含水ア
セトン又は含水エタノールから再結晶させる方法である
。First, in the first method, a mixture of isomers of clemastine and (4
) with monotartaric acid in the presence of acetone, filtered,
This is a method in which acetone is distilled off from the resulting tartrate salt, and then recrystallized from aqueous acetone or aqueous ethanol.
この方法において酒石酸塩を濾別した濾夜にアセトンを
添加して還流処理すれば異性体1及びの酒石酸塩が得ら
れ、これら異性体の酒石酸塩を濾汎ルた濾液を中和して
遊離塩基となした後に(ニ)一酒石酸を添加して反応さ
せれば異性体(ニ)一酒石酸塩が得られ、この異性体の
酒石酸塩を濾別した濾夜を再び中和して遊離塩基となせ
ば、これは再び第1方法の出発物質として使用すること
ができる。第2方法は、クレマスチンの異性体混合物と
(4)−酒石酸とをアセトンの存在下に還流処理し、反
応混合物を濾過し、濾夜より、アセトンを留去し、生成
する酒石酸塩を次いで含水アセトン又は含水エタノール
から再結晶させる方法である。In this method, if acetone is added to the filter cake after filtering off the tartrate and refluxing it, isomer 1 and the tartrate are obtained, and the tartrate of these isomers is released by neutralizing the filtered filtrate. If (d) monotartaric acid is added and reacted after forming a base, the isomer (d) monotartrate is obtained, and the filtered residue from which the tartrate of this isomer is filtered off is again neutralized to form a free base. If so, it can be used again as starting material for the first method. The second method involves refluxing a mixture of clemastine isomers and (4)-tartaric acid in the presence of acetone, filtering the reaction mixture, distilling off the acetone from the filter, and then hydrating the resulting tartrate. This method involves recrystallization from acetone or aqueous ethanol.
この第2方法に於て、還流処理には約6時間程度要し、
これにより生ずる固形物は異性体1との酒石酸塩混合物
である。第3方法は、クレマスチンの異性体混合物と(
ニ)酒石酸とをアセトンの存在下に還流処理し反応混合
物を濾過し、濾液よりアセトンを留去し生成する(ニ)
酒石酸塩を遊離塩基として回収し…一酒石酸とアセトン
の存在において反応させ、反応混合物からアセトンを留
去し、次いで含水アセトンまたは含水エタノールから再
結晶させる方法である。In this second method, the reflux treatment requires about 6 hours,
The resulting solid is a tartrate mixture with isomer 1. The third method uses a mixture of isomers of clemastine and (
d) Tartaric acid is refluxed in the presence of acetone, the reaction mixture is filtered, and acetone is distilled off from the filtrate to produce (d)
In this method, tartrate is recovered as a free base, reacted with monotartaric acid in the presence of acetone, acetone is distilled off from the reaction mixture, and then recrystallized from aqueous acetone or aqueous ethanol.
第4方法は、粗製クレマスチンを有機酸塩例えばコハク
酸塩、フマール酸塩にて精製し、得られるクレマスチン
遊離塩基と…一酒石酸とを反応させ、次いで含水アセト
ンまたは含水エタノールより再結晶する方法である。然
るに、各種有機酸につき分割剤としての使用可能性を検
討した結果、(4)一酒石酸および(ニ)酒石酸はアセ
トンを溶媒として用いる場合に有効であり、又再結晶に
際して純アセトンを溶媒として用いる場合には、再現性
、収率等に問題を生ずるか、溶媒として含水アセトン又
は含水エタノールを用いる場合には、これ等が改善され
ることが見出された。The fourth method is to purify crude clemastine with an organic acid salt such as succinate or fumarate, react the resulting clemastine free base with monotartrate, and then recrystallize from aqueous acetone or aqueous ethanol. be. However, as a result of examining the possibility of using various organic acids as resolving agents, we found that (4) monotartaric acid and (d) tartaric acid are effective when acetone is used as a solvent, and pure acetone is used as a solvent during recrystallization. It has been found that in some cases, problems arise in reproducibility, yield, etc., or that these problems can be improved if aqueous acetone or aqueous ethanol is used as a solvent.
斯くして、本発明の目的は、(4)一酒石酸を分割剤と
し、再結晶溶媒として含水アセトン、又は含水エタノー
ルを用いるフマール酸クレマスチンの製法を提供するこ
とである。Thus, an object of the present invention is to provide (4) a method for producing clemastine fumarate using monotartaric acid as a resolving agent and aqueous acetone or aqueous ethanol as a recrystallization solvent.
本発明の第1方法は、クレマスチンの異性体混合物と…
一酒石酸とをアセトンの存在に於て反応せしめ、淵過し
、得られる酒石酸塩よりアセトンを留出し含水アセトン
又は含水エタノールより再結晶せしめることを特徴とす
る。The first method of the present invention comprises a mixture of isomers of clemastine and...
It is characterized in that it is reacted with monotartaric acid in the presence of acetone, filtered, and acetone is distilled from the resulting tartrate and recrystallized from aqueous acetone or aqueous ethanol.
この方法に於て酒石酸塩を淵別した淵液にアセトンを添
加して還流処理すれば、異性体1及びの酒石酸塩が得ら
れ、これ等異性体の酒石酸塩を淵別した淵夜を中和して
遊離塩基となし、(ニ)一酒石酸を添加して反応せしめ
れば異性体(ニ)一酒石酸塩が得られ、該異性体の酒石
酸塩を済別した戸夜を再び中和して遊離塩基となせば、
これは再び本第1方法の出発物質として使用することが
できる。In this method, if acetone is added to the liquid from which the tartrate has been separated and the liquid is refluxed, isomer 1 and tartrate can be obtained. When the isomer (d) monotartrate is obtained by adding (d) monotartrate and reacting, the toya which has removed the tartrate of the isomer is again neutralized. If it is made into a free base,
This can again be used as starting material for this first method.
本発明の第2方法は、クレマスチンの異性体混合物と…
一酒石酸とをアセトンの存在に於て還流処理し、反応混
合物をろ過し、済液より、アセトンを留去し、生成する
酒石酸塩を含水アセトン又は含水エタノールより再結晶
せしめることを特徴とする。The second method of the present invention uses a mixture of isomers of clemastine and...
The method is characterized by refluxing monotartaric acid in the presence of acetone, filtering the reaction mixture, distilling off acetone from the distilled liquid, and recrystallizing the resulting tartrate from aqueous acetone or aqueous ethanol.
第2方法に於て、還流処理には約6時間程度要する。In the second method, the reflux treatment requires about 6 hours.
この処理に依り生ずる固形物は異性体1との酒石酸塩混
合物である。本発明の第3方法は、クレマスチンの異性
体混合物と(ニ)酒石酸とをアセトン存在において還流
処理し反応混合物を淵過し、その淵液よりアセトンを留
去し生成する(ニ)酒石酸塩を遊離塩基として回収し…
一酒石酸とアセトンの存在において反応せしめアセトン
を留去し、含水アセトンまたは含水エタノ一ルより再結
晶せしめることを特徴とする。The solid resulting from this treatment is a tartrate mixture with isomer 1. The third method of the present invention is to reflux a mixture of clemastine isomers and (d) tartaric acid in the presence of acetone, filter the reaction mixture, and distill off acetone from the bottom liquid to produce (d) tartrate. Recovered as free base...
It is characterized by reacting in the presence of monotartaric acid and acetone, distilling off the acetone, and recrystallizing from hydrous acetone or ethanol.
本発明の第4方法は、粗製クレマスチンを有機酸塩例え
ばコハク酸塩、フマール酸塩にて精製しまた、4種の異
性体より分離された異性体■…酒石酸塩の比旋光度は+
23〜+25が望ましいが医薬として有用であるフマー
ル酸クレマスチンの原料としては+21〜+26.5の
純度を必要とする。次に、参考例及び実施例に関連して
本発明を更に詳細に説明する。In the fourth method of the present invention, crude clemastine is purified using an organic acid salt such as succinate and fumarate, and the isomer separated from four types of isomers (1)...The specific rotation of tartrate is +
A purity of 23 to +25 is desirable, but a purity of +21 to +26.5 is required as a raw material for clemastine fumarate, which is useful as a medicine. Next, the present invention will be explained in more detail with reference to reference examples and examples.
参考例
クレマスチンの合成
;)α−メチル−p−クロロベンツヒドロールの合成マ
グネシウム60.89(2.5グラム原子)、沃素2,
59、無水エーテル700mlに攪拌下にブロモベンゼ
ン3709(2.35モノ(ハ)及びエーテル400m
lの溶液を緩やかに還流する程度に滴下し、完了後更に
2時間還流させてグリニヤール試薬を調製する。Reference Example Synthesis of Clemastine;) Synthesis of α-methyl-p-chlorobenzhydrol Magnesium 60.89 (2.5 gram atoms), Iodine 2,
59. Add bromobenzene 3709 (2.35 mono(c)) and 400 ml of ether to 700 ml of anhydrous ether with stirring.
A Grignard reagent is prepared by adding 1 of the solution dropwise to the solution until it gently refluxes, and then refluxing for an additional 2 hours.
該グリニヤール試薬を0℃以下に冷却し、これにp−ク
ロロアセトフエノン2809(1.81モノ(ハ)とエ
ーテル400mlとから成る溶夜をO〜−5℃に於て滴
下し、然る後15分間還流処理し再びO℃以下に冷却し
、飽和塩化アンモニウム水溶夜約400mlを滴下して
分解し、エーテル層を分取し、水洗し、無水硫酸ナトリ
ウムにて乾燥し、溶媒を留去すれば残留液体として目的
物約4109(収率973%)が得られる。11)2−
(2−クロロエチノ(ハ)−1−メチルピロリジンの合
成1−メチル−2−ピロリジンエタノ一ル
103.29(0.8モノ(ハ)とクロロホルム500
aとから成る溶液を、室温に於て乾燥塩化水素ガスにて
飽和せしめ、10℃以下に冷却し、次いで約10分間で
塩化チオニル196.5g(1.65モノ(ハ)を滴下
し、加温し、浴温7『Cにて2時間還流処理する。The Grignard reagent was cooled to below 0°C, and a solution consisting of p-chloroacetophenone 2809 (1.81 mono(III) and 400 ml of ether) was added dropwise at 0 to -5°C. After that, the mixture was refluxed for 15 minutes, cooled again to below 0°C, and decomposed by dropping about 400 ml of a saturated aqueous ammonium chloride solution.The ether layer was separated, washed with water, dried over anhydrous sodium sulfate, and the solvent was distilled off. By doing so, the target product approximately 4109 (yield 973%) is obtained as a residual liquid.11) 2-
(Synthesis of 2-chloroethyno(c)-1-methylpyrrolidine 1-methyl-2-pyrrolidine ethanol 103.29 (0.8 mono(c) and chloroform 500
The solution consisting of a was saturated with dry hydrogen chloride gas at room temperature, cooled to below 10°C, and then 196.5 g of thionyl chloride (1.65 mono(c)) was added dropwise over about 10 minutes. Heat and reflux for 2 hours at a bath temperature of 7°C.
然る後溶媒を留去し、3N一水酸化ナトリウム溶液55
0mlを添加し、エーテル340mlにて抽出し、水層
に、強冷下に、固形水酸化カリウム1009を添加し、
エーテル各340mlにて3回抽出し、合併エーテル抽
出物を伽A(.硫酸ナトリウムにて乾燥し、溶媒を留去
し、残留物を沸点47℃/5Hg乃至沸点65〜6℃/
11mmHgにて減圧蒸留すれば目的物1069(収率
89.8%)が得られる。After that, the solvent was distilled off and 3N sodium monohydroxide solution 55%
0 ml was added, extracted with 340 ml of ether, and solid potassium hydroxide 1009 was added to the aqueous layer under strong cooling.
The combined ether extracts were extracted three times with 340 ml each of ether, dried over sodium sulfate, the solvent was distilled off, and the residue was separated from boiling point 47°C/5Hg to boiling point 65-6°C/
Distillation under reduced pressure at 11 mmHg yields the target product 1069 (yield 89.8%).
111)クレマスチンの合成
ベンゼン300mlにナトリウムアミド粉末399(1
.Oモノりを懸濁せしめ、これに;)項記載の方法によ
り得たるα−メチル−p−クロロベンツヒドロール20
09(0.86モノ(ハ)を滴下し(べンゼン100m
lにて滴下ロート等を洗浄)、徐々に加混し1〜4時間
還流処理した後に、ii)項記載の方法に依り得たる、
2−(2−クロロエチノ(ハ)−1−メチルピロリジン
1069(0.72モノ(ハ)を約30分間かけて滴゛
下(べンゼン50mlにて滴下ロート等を洗浄)し、2
0時間還流処理し5、冷後水200mlにて洗浄し、有
機層にエーテル300mlを添加し、2N一塩酸各43
0mlにて4回抽出し、合併塩酸抽出液を再びエーテル
洗浄し、6N一水酸化ナトリウム水溶液500m′にて
アルカリ性となし、エーテル各300mlにて2回抽出
し、合併抽出物を炭酸カリウムにて乾燥し、溶媒を留去
し、残留物を沸点154°C/0.O2mmHgにて減
圧蒸留すれぱ油状物として目的物質の粗製物191g(
収率77.4%)が得られる。111) Synthesis of clemastine Sodium amide powder 399 (1
.. α-methyl-p-chlorobenzhydrol 20 obtained by the method described in section ;
09 (dropping 0.86 mono(c) (benzene 100 m
After gradually adding the mixture and refluxing for 1 to 4 hours, the method described in section ii) can be applied.
Add 2-(2-chloroethino(c)-1-methylpyrrolidine 1069 (0.72 mono(c)) dropwise over about 30 minutes (washing the dropping funnel etc. with 50 ml of benzene),
Reflux treatment for 0 hours 5. After cooling, wash with 200 ml of water, add 300 ml of ether to the organic layer, and add 43 ml each of 2N monohydrochloric acid.
The combined hydrochloric acid extract was washed with ether again, made alkaline with 500ml of 6N sodium monohydroxide aqueous solution, extracted twice with 300ml each of ether, and the combined extract was washed with potassium carbonate. Dry, evaporate the solvent and reduce the residue to a boiling point of 154°C/0. Distilled under reduced pressure at 02 mmHg to obtain 191 g of the crude target substance as an oil (
A yield of 77.4%) is obtained.
lV)粗製クレマスチンの精製
ワコーゲルC−200,7009を用い粗製油状物(上
記111)項記載の方法に依り得られたもの)259を
カラムクロマトグラフイーで分離精製した。lV) Purification of Crude Clemastine Using Wako Gel C-200, 7009, crude oil (obtained by the method described in Section 111) above 259 was separated and purified by column chromatography.
展開溶媒及び留出量は下記の通りであり、回収率は95
%遊離塩基は80〜85%であつた。展開溶媒
トリエチルアミンと酢酸エチルとn−ヘキサンとの1.
2:2:10混合物実施例 1
′、tJL1−1??t?、
ン油状物1.0059をアセトン10m1にて溶解し、
これに…一酒石酸0.4379を添加して加熱溶解させ
た後溶媒を留去し、生成する酒石酸塩を80%アセトン
水溶液3m1から4℃に於て再結晶せしめ、次いで90
%アセトン水溶夜1m1から再結晶(4℃)せしめれば
、異性体の粗製酒石酸塩258η(収率119%)が得
られる。The developing solvent and distillation amount are as follows, and the recovery rate is 95
The % free base was 80-85%. 1. Developing solvent triethylamine, ethyl acetate, and n-hexane.
2:2:10 Mixture Example 1', tJL1-1? ? T? , Dissolve 1.0059 of the oily substance in 10 ml of acetone,
To this... 0.4379 of monotartaric acid was added and dissolved by heating, then the solvent was distilled off, and the resulting tartrate was recrystallized from 3 ml of an 80% acetone aqueous solution at 4°C.
Recrystallization (at 4° C.) from 1 ml of an aqueous solution of % acetone gives 258 η of the crude tartrate of the isomer (yield: 119%).
上記異性体1Vの酒石酸塩を淵別した淵液の溶媒を留去
し、アセトン5m1にて数時間還流処理し、析出結晶を
淵別後にF5液を1N一水酸化ナトリウム溶夜にて中和
し、エーテルにて抽出し遊離塩基とする。After separating the tartrate of isomer 1V, the solvent of the solution was distilled off, refluxed with 5 ml of acetone for several hours, and after separating the precipitated crystals, the F5 solution was neutralized with 1N sodium monohydroxide solution. and extract with ether to obtain the free base.
この塩基を(ニ)一酒石酸塩となし、上記と同様の操作
を繰り返せば粗製の異性体の(ニ)一酒石酸塩が得られ
るので、この戸液を処理して再度…一酒石酸塩となし、
上記と同様の処理を行えば、異性体の粗製酒石酸塩が得
られる。If you convert this base into (d) monotartrate and repeat the same operation as above, you will obtain the crude isomer (d) monotartrate, so treat this solution and convert it to monotartrate again. ,
By carrying out the same treatment as above, the crude tartrate of the isomer is obtained.
(収率6。4%)粗製異性体の酒石酸塩はエタノール/
ヘキサンから再結晶せしめることに依り精製することが
できる。(Yield 6.4%) The crude isomer tartrate was prepared using ethanol/
It can be purified by recrystallization from hexane.
この精製結晶を水に懸濁させ、水酸化ナトリウムにてア
ルカリ性となし、エーテル抽出すれば油状物として異性
体が得られる。The purified crystals are suspended in water, made alkaline with sodium hydroxide, and extracted with ether to obtain the isomer as an oil.
(ロ)D=+36.5ら(1〜2%メタノール中)この
異性体をエタノール中フマール酸塩となしエタノールよ
り再結晶すると巾。(b) D=+36.5 (in 1-2% methanol) When this isomer is converted into a fumarate salt in ethanol and recrystallized from ethanol, the width is obtained.
+16.9(2%メタノール)融点176〜180結C
(分解)のフマール酸クレマスチンが得られる。+16.9 (2% methanol) melting point 176-180C
(decomposition) of clemastine fumarate is obtained.
実施例 2
参考例記載の方法に依り得たる、クレマスチン油状物1
.219と…一酒石酸0,539とをアセトン5m1中
に溶解せしめ6時間還流処理した後、温時済過すれば8
287r19の結晶(収率47,6%)が得られる。Example 2 Clemastine oil 1 that can be obtained by the method described in Reference Example
.. 219 and 0.539 bitartaric acid were dissolved in 5 ml of acetone, refluxed for 6 hours, and then aged at a temperature to give 8.
Crystals of 287r19 (yield 47.6%) are obtained.
この結晶の融点は141〜180℃であり異性体1との
酒石酸混合物である。This crystal has a melting point of 141-180°C and is a mixture of tartaric acid and isomer 1.
上記結晶を戸別した淵夜よりアセトンを留去し、80%
アセトン水溶液1.7m1にて4℃に於て再結晶すれば
374〜(収率21.5%)の結晶が得られる。Acetone was distilled off from the above crystals from Fuchiya, and 80%
Recrystallization from 1.7 ml of acetone aqueous solution at 4 DEG C. yields crystals of 374~ (yield 21.5%).
90%アセトン水溶夜1m1から再結晶せしめれば、2
05W19(収率11.8%)の異性体の酒石酸塩が得
られる。If recrystallized from 1 ml of 90% acetone solution, 2
The isomeric tartrate salt of 05W19 (yield 11.8%) is obtained.
以下実施例1と同様に処理するとMpl76〜180℃
(分解)(社)D+16.6フマール酸クレマスチンが
得られる。When treated in the same manner as in Example 1, Mpl76-180℃
(Decomposition) (Company) D+16.6 clemastine fumarate is obtained.
実施例 3〜6
参考例記載の方法に依り得たる精製クレマスチン油状物
10.059をアセトン100m1に溶解せしめ、…一
酒石酸4.371を添加して加熱溶解させた後溶媒を留
去する。Examples 3 to 6 10.059 ml of purified clemastine oil obtained by the method described in Reference Examples is dissolved in 100 ml of acetone, 4.371 ml of monotartaric acid is added and dissolved by heating, and then the solvent is distilled off.
これを用い含水アセトン、含水エタノールにて分割した
結果は下記の通りであつた。This was separated using aqueous acetone and aqueous ethanol, and the results were as follows.
実施例 7
参考例記載の方法により得たる精製クレマスチン油状物
59をアセトン18mlに溶解し、これに(ニ)酒石酸
2.189を添加し5時間還流せしめ放冷後析出する結
晶を済別し、そのP夜の溶媒を留去し、残留物を1N水
酸化ナトリウム溶液にてアルカリ性としエーテル抽出し
、得られる遊離塩基(約2.49)と…酒石酸1.O5
9をアセトン8mlに加温溶解し溶媒を留去したのち8
0%アセトン3.5mlより再結晶すれば融点77〜1
00℃の異性体■…酒石酸塩1.185g(収率16.
5%)が得られる。Example 7 Purified clemastine oil 59 obtained by the method described in Reference Example was dissolved in 18 ml of acetone, 2.189 g of (d)tartaric acid was added thereto, refluxed for 5 hours, and after cooling, precipitated crystals were removed, The solvent was distilled off, the residue was made alkaline with 1N sodium hydroxide solution and extracted with ether, and the resulting free base (approximately 2.49) and tartaric acid 1. O5
After heating and dissolving 9 in 8 ml of acetone and distilling off the solvent, 8
If recrystallized from 3.5ml of 0% acetone, the melting point will be 77-1.
00°C isomer ■...tartrate 1.185g (yield 16.
5%) is obtained.
この酒石酸塩1.09を1N水酸化ナトリウムにてアル
カリ性としエーテル抽出し得られる遊離塩基にフマール
酸0.2359とエタノ一ル12mlを加え、加温溶解
し放冷後析出するフマール酸塩を再度エタノ一ルより再
結晶すれば、融点178〜1800C(分解)のフマー
ル酸クレマスチン0.7259(収率77.9%)が得
られる。1.09 of this tartrate was made alkaline with 1N sodium hydroxide and extracted with ether. To the resulting free base, 0.2359 of fumaric acid and 12 ml of ethanol were added, dissolved by heating, and after cooling, the precipitated fumarate was again removed. If recrystallized from ethanol, clemastine fumarate 0.7259 (yield 77.9%) with a melting point of 178 to 1800 C (decomposition) is obtained.
実施例 8参考例11j)記載の方法により得たる粗製
クレマスチン油状物59にアセトン15mlコハク酸1
.759を加え加温して溶解し、室温放置により析出す
るコハク酸塩をエタノ一ル:n−ヘキサン(3:1)3
0mlにて再結晶すれば融点127〜130℃のコハク
酸塩3.29(収率47.64%)が得られる。Example 8 Reference Example 11j) To the crude clemastine oil obtained by the method described in 59, 15 ml of acetone and 1 succinic acid were added.
.. 759 was added and dissolved by heating, and the succinate that precipitated by standing at room temperature was mixed with ethanol:n-hexane (3:1) 3
Recrystallization in 0 ml yields 3.29 succinates (yield 47.64%) with a melting point of 127-130°C.
この結晶2.99を10%水酸化ナトリウム液にてアル
カリ性としエーテル抽出して得られるクレマスチン遊離
塩基に…酒石酸0.9439、95%アセトン9.3m
lを加え、加温溶解し室温に放置して析出する結晶を9
0%アセトンより再結晶せしめれば融点74〜110℃
の異性体■(ト)酒石酸塩0.8589(収率27.7
%)(社)。Clemastine free base obtained by making 2.99 of these crystals alkaline with 10% sodium hydroxide solution and extracting with ether...tartaric acid 0.9439, 95% acetone 9.3m
1, dissolved by heating, and left to stand at room temperature to precipitate crystals.
When recrystallized from 0% acetone, the melting point is 74-110℃.
Isomer ■(t)tartrate 0.8589 (yield 27.7
%) (company).
Claims (1)
ンを溶媒としてクレマスチンの異性体混合物から医薬と
して有用なフマール酸クレマスチンを製造する方法にお
いて、精製用再結晶溶媒として含水アセトン又は含水エ
タノールを用いることを特徴とする、医薬として有用な
フマール酸クレマスチンの製法。1. In a method for producing clemastine fumarate useful as a pharmaceutical from a mixture of clemastine isomers using (+) or (-)-tartaric acid as a resolving agent and acetone as a solvent, aqueous acetone or aqueous ethanol is used as a recrystallization solvent for purification. A method for producing clemastine fumarate useful as a medicine, characterized in that it is used as a medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15796176A JPS5927333B2 (en) | 1976-12-28 | 1976-12-28 | Process for producing clemastine fumarate useful as a medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15796176A JPS5927333B2 (en) | 1976-12-28 | 1976-12-28 | Process for producing clemastine fumarate useful as a medicine |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5382773A JPS5382773A (en) | 1978-07-21 |
JPS5927333B2 true JPS5927333B2 (en) | 1984-07-05 |
Family
ID=15661226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP15796176A Expired JPS5927333B2 (en) | 1976-12-28 | 1976-12-28 | Process for producing clemastine fumarate useful as a medicine |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5927333B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102816101A (en) * | 2012-08-21 | 2012-12-12 | 江苏恒祥化工有限责任公司 | Synthesis method of (S)-N-methyl-2 chloro-ethyl-pyrrolidine |
CN114324673B (en) * | 2022-01-12 | 2023-06-20 | 山东百诺医药股份有限公司 | Analysis method for simultaneously determining clemastine fumarate and isomer thereof |
-
1976
- 1976-12-28 JP JP15796176A patent/JPS5927333B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
JPS5382773A (en) | 1978-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stork et al. | The Stereochemistry of the SN2'Reaction. II1 | |
JP2014074033A (en) | Methods for isolating propargylated aminoindanes | |
JPS604146A (en) | 3-(3-hydroxybutoxy)-1-butanol and manufacture | |
EP1129066A1 (en) | Production of 2-amino-2- 2-(4-c 2-20?-alkyl-phenyl)ethyl]propane-1,3-diols | |
JPS5817474B2 (en) | Yuukikagoubutsuni Cansurukairiyou | |
JPS5927333B2 (en) | Process for producing clemastine fumarate useful as a medicine | |
JPH08291106A (en) | Production of optically active 2-propyloctanoic acid | |
JP2001261644A (en) | Hexahydroisoindoline acid-addition salt and method for applying the same | |
Pallavicini et al. | Resolution of β-unsaturated amines with isopropylidene glycerol hydrogen phthalate | |
CN111777554A (en) | Method for synthesizing cisatracurium besilate | |
JPWO2004000795A1 (en) | Process for producing vinyl perfluoroalkanesulfonic acid ester derivatives | |
JPH037272A (en) | Production of optically active tetrahydro-2-furoic acid | |
CN106928139B (en) | A kind of shellfish reaches the synthetic method of quinoline impurity | |
JP6385580B2 (en) | Process for large-scale production of N- [4- (1-cyclobutylpiperidin-4-yloxy) phenyl] -2- (morpholin-4-yl) acetamide dihydrochloride | |
CN115197115B (en) | Preparation method and application of chiral 5-oxo pyrrolidine-3-carboxylic acid | |
JPS598259B2 (en) | New cyclohexene derivative | |
JP2003137835A (en) | Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid | |
FR2555580A1 (en) | NOVEL AZABICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | |
CN108191625B (en) | (E) Preparation method of (E) -1- (4-hydroxy-3-methoxyphenyl) -4-en-3-decanone | |
TW426685B (en) | Diastereomeric esters of etodolac-an antiarthritic drug and method for the optical resolution of etodolac | |
JPS6051465B2 (en) | 3-Methyl-3-[4-(1-oxo-2-isoindolinyl)phenyl]pyruvic acid esters | |
JPH0725874A (en) | Production of optically active 3-amino-2-benzhydrylquinuclidine compound | |
CN115611739A (en) | Preparation method of benzoic acid intermediate and intermediate thereof | |
JPH0813793B2 (en) | Tartaric acid amide derivative | |
JPH08104666A (en) | Production of 4-isopropyl cyclohexanecarboxylic ester derivative |